Development, Optimization & Evaluation Of Solid Lipid Nanoparticles Of Celecoxib.

Celecoxib belongs to the category of nonsteroidal anti-inflammatory drug having poor oral bioavailability caused by the first-pass metabolism. Work in present to improve the oral bioavailability of celecoxib by incorporating into SLNs. Several celecoxib loaded formulation of SLNs were formulated using lipid by a method known as solvent emulsification-diffusion method and optimization is done by central composite drug design. The physical compatibility study of drug excipients was done by FTIR. Optimizes celecoxib loaded-SLNs have particle size in range of 314 nm with entrapment efficiency varying in between 79% was developed. The comparision between the data of ex-vivo release and marketed formulation was done. It showed an important difference observed between marketed formulation and optimized formulation. The data of optimized formulation released and was subjected to many release kinetic model, the model known as Higuchi kinetic was found to be best fitted with R2=0.955. The result obtained shows that the SLNs are potential lipid carrier for the improvement of celecoxib by the minimization of the first pass metabolism.